LG Chem to make first domestic 6-in-1 vaccine for infants

Investment of $156 mn in clinical development of APV006 and facility construction will enable commercial use from 2030

Researchers of LG Chem R&D center (Courtesy of LG Chem) 
Researchers of LG Chem R&D center (Courtesy of LG Chem) 
Yoo-Rim Kim 1
2023-08-01 15:09:31 youforest@hankyung.com
Bio & Pharma


South Korea's LG Chem Ltd. will produce the nation's first homegrown six-in-one vaccine for infants, something that the country is entirely reliant on imports.

The company on Tuesday said it registered its first tester for the domestic phase 1 clinical trial of APV006.

APV006 prevents six infectious diseases: diphtheria, tetanus, whooping cough, polio, meningitis and hepatitis B. It contains a hepatitis B-preventive effect added to a five-in-one vaccine and requires two fewer shots than the latter.

In phase 1 clinical trials on 42 healthy adults at Seoul National University Hospital, the company will evaluate APV006's safety and immunogenicity, or the ability of cells and tissues to provoke an immune response, compared to a previously commercialized six-in-one vaccine.

LG Chem pledged to play a role in stable supply chains by developing the country's first domestically developed six-in-one infant vaccine. The France-based multinational pharmaceutical and healthcare company Sanofi is the country's lone supplier of such a vaccine.

The clinical development of APV006 and related facility construction will cost an estimated 200 billion won ($156.1 million), with commercial application expected before 2030.

"Given fears over shortages, a highly significant development task is to prepare an environment in which our children can stably receive essential vaccines by localizing all technologies for manufacturing original solutions for six-in-one vaccines," said Son Jee-woong, head of LG Chem's Life Sciences division.

"We will expedite domestic commercialization through timely investment and actively contribute to the prevention of infectious disease worldwide by continuously expanding the number of countries to enter."

To enter the procurement market for international organizations, LG Chem is also conducting phase 2 clinical trials of LBVD, a six-in-one whole cell pertussis-based vaccine that uses whole pertussis bacteria to prevent diphtheria, tetanus, whooping cough, hepatitis B, meningitis and poliomyelitis.

Write to Yoo-Rim Kim at youforest@hankyung.com

LG Chem in talks with Glenwood to sell off diagnostics unit

LG Chem in talks with Glenwood to sell off diagnostics unit

Biopharmaceutical research laboratory (Courtesy of Getty Images) LG Chem Ltd. is slated for exclusive talks with Seoul-based Glenwood Private Equity to sell off its in vitro diagnostics business, according to biopharmaceutical industry sources on Wednesday.The South Korean conglomerate LG Group

LG Chem to launch new diabetes combination drug Zemidapa

LG Chem to launch new diabetes combination drug Zemidapa

South Korean chemical company LG Chem Ltd. has announced the release of a new diabetes combination drug, Zemidapa Tab, set to launch on Apr. 8. The drug is based on the active ingredient gemigliptin, known as Zemiglo, and dapagliflozin, both leading products in their respective markets of DP

LG Chem mulls shuttering in-vitro diagnostics business

LG Chem mulls shuttering in-vitro diagnostics business

LG Chem diagnostic reagent factory in Osong, Korea (Courtesy of LG Chem) LG Chem Ltd. is considering an exit from the in-vitro diagnostics market to focus more on novel drug development as it lagged its smaller local rivals in riding the COVID-19 diagnostic reagent boom. According to sourc

LG Chem builds S.Korea's first plant for clinical trials

LG Chem builds S.Korea's first plant for clinical trials

LG Chem completed the $571 million purchase of the US biotech firm AVEO Pharmaceuticals in January LG Chem Ltd. has built South Korea’s first pharmaceutical plant dedicated to clinical trials, which the company expects to speed up its medicine development by directly handling drug candida

LG Chem completes acquisition of US biotech firm AVEO

LG Chem completes acquisition of US biotech firm AVEO

LG Chem Vice Chair Shin Hak-cheol (fourth from left) and AVEO CEO Michael Bailey (fourth from right) on Jan. 19 (Courtesy of LG Chem) LG Chem Ltd. is set to complete its $571 million purchase of the US biotech firm AVEO Pharmaceuticals Inc. on Friday, which would strengthen its anti-cancer drug

LG Chem in $95.5 million drug out-licensing deal with China’s Innovent

LG Chem in $95.5 million drug out-licensing deal with China’s Innovent

LG Chem Life Sciences researchers LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., and China’s biotech company Innovent Biologics have entered into a strategic collaboration and licensing agreement regarding LG’s Tigulixostat, a late-stage novel gout treatment.Unde

LG Chem confirms diabetes drug Zemidapa's efficacy in phase 3 trials

LG Chem confirms diabetes drug Zemidapa's efficacy in phase 3 trials

LG Chem researchers LG Chem Ltd. announced in a disclosure on Monday that it had confirmed superior efficacy in phase 3 clinical trials for the combined administration of Zemidapa, a new treatment for diabetes.Zemidapa is a combination medication with two drug ingredients that contain LG Chem's

LG Chem receives FDA nod for CUE-102 cancer treatment phase 1 trials

LG Chem receives FDA nod for CUE-102 cancer treatment phase 1 trials

LG Chem researchers LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., has received the US Food and Drug Administration’s approval for phase 1 clinical tests of its cancer treatment candidate CUE-102.The South Korean company said on Thursday the clinical trials will be con

(* comment hide *}